IVVD Stock Price, Analysis & Fundamentals

Analysis

Invivyd, Inc. is a biotechnology company operating within the healthcare sector. With a market capitalization of $594.46M and revenue of $50.04M, it is a relatively small-scale entity compared to its peers in the industry. The company has 99 employees. The financial health of Invivyd, Inc. is characterized by significant losses. The net income (TTM) is -$59,862,000, while EBITDA and free cash flow are also negative at -$60,544,000 and -$38,007,248, respectively. However, the company has a substantial amount of cash on hand with $84.97M in cash reserves. The debt-to-equity ratio is 2.88, indicating relatively high leverage. In terms of profitability, the gross margin stands at 93.3%, but operating and profit margins are negative at -84.0% and -119.6%, respectively. The valuation context for Invivyd, Inc. is notable due to its negative forward P/E ratio (-18.89) and EV/EBITDA (-8.27), which suggests that the market may be pricing in significant losses or potential turnaround opportunities. The revenue growth rate (YoY) of 41.2% indicates some level of increase in sales, but earnings growth is not available.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Invivyd, Inc.

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Visit website →

IVVD

Price History (1Y)

Analysis

About Invivyd, Inc.

Key Statistics

Company Info